A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology

Dermatology Online Journal

Volumn 20, Issue 5, 2014, Pages

  Moustafa, Farah ^a   Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

AN2728; Apremilast; Atopic dermatitis; Inflammation; Phosphodiesterase inhibitor; Psoriasis

Indexed keywords

ADENYLATE CYCLASE; AN 2728; APREMILAST; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP; CYCLOSPORIN; DERMATOLOGICAL AGENT; ETRETIN; G PROTEIN COUPLED RECEPTOR; METHOTREXATE; PHOSPHODIESTERASE; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE IX; PHOSPHODIESTERASE V; PHOSPHODIESTERASE VI; PHOSPHODIESTERASE VII; PHOSPHODIESTERASE VIII; PHOSPHODIESTERASE X; PHOSPHODIESTERASE XI; PLACEBO; SPLEEN EXONUCLEASE; UNCLASSIFIED DRUG; AN2728; BORON DERIVATIVE; FUSED HETEROCYCLIC RINGS; NONSTEROID ANTIINFLAMMATORY AGENT; THALIDOMIDE;

ANTIINFLAMMATORY ACTIVITY; ATOPIC DERMATITIS; CONTROLLED STUDY; DERMATOLOGY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; HEADACHE; HUMAN; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCORING SYSTEM; SIGNAL TRANSDUCTION; VOMITING; ANALOGS AND DERIVATIVES; DERMATITIS, ATOPIC; METABOLISM; PHYSIOLOGY; TISSUE DISTRIBUTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BICYCLO COMPOUNDS, HETEROCYCLIC; BORON COMPOUNDS; CYCLIC AMP; DERMATITIS, ATOPIC; HUMANS; PHOSPHODIESTERASE 4 INHIBITORS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PSORIASIS; THALIDOMIDE; TISSUE DISTRIBUTION;

EID: 84901193124     PISSN: 10872108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Deree J, Martins JO, Melbostad H, Loomis WH, Coimbra R. Insights into the regulation of TNF-alpha production in human mononuclear cells: the effects of non-specific phosphodiesterase inhibition. Clinics (Sao Paulo) 2008;63:321-328.[PMID: 18568240]
2. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998;157:351-370.[PMID: 9476844]
3. Asadullah K, Sterry W, Stephanek K et al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 1998;101:783-794.[PMID: 9466973]
4. Trepicchio WL, Ozawa M, Walters IB et al. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 1999;104:1527-1537.[PMID: 10587516]
5. Nomura I, Goleva E, Howell MD et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 2003;171:3262-3269.[PMID: 12960356]
6. Zambon AC, Zhang L, Minovitsky S et al. Gene expression patterns define key transcriptional events in cell-cycle regulation by cAMP and protein kinase A. Proc Natl Acad Sci U S A 2005;102:8561-8566.[PMID: 15939874]
7. Serezani CH, Ballinger MN, Aronoff DM, Peters-Golden M. Cyclic AMP: master regulator of innate immune cell function. Am J Respir Cell Mol Biol 2008;39:127-132.[PMID: 18323530]
8. Konrad FM, Neudeck G, Vollmer I, Ngamsri KC, Thiel M, Reutershan J. Protective effects of pentoxifylline in pulmonary inflammation are adenosine receptor A2A dependent. FASEB J 2013;27:3524-3535.[PMID: 23699177]
9. Justinova Z, Ferre S, Barnes C et al. Effects of chronic caffeine exposure on adenosinergic modulation of the discriminativestimulus effects of nicotine, methamphetamine, and cocaine in rats. Psychopharmacology (Berl) 2009;203:355-367.[PMID: 18688601]
10. Medina AE. Vinpocetine as a potent antiinflammatory agent. Proc Natl Acad Sci U S A 2010;107:9921-9922.[PMID: 20495091]
11. Szczypka M, Obminska-Mrukowicz B. Modulating effects of nonselective and selective phosphodiesterase inhibitors on lymphocyte subsets and humoral immune response in mice. Pharmacol Rep 2010;62:1148-1158.[PMID: 21273672]
12. Alhathal N, Elshal AM, Carrier S. Synergetic effect of testosterone and phophodiesterase-5 inhibitors in hypogonadal men with erectile dysfunction: A systematic review. Can Urol Assoc J 2012;6:269-274.[PMID: 23093538]
13. Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 2005;10:1503-1519.[PMID: 16257373]
14. Tenor H, Hedbom E, Hauselmann HJ, Schudt C, Hatzelmann A. Phosphodiesterase isoenzyme families in human osteoarthritis chondrocytes--functional importance of phosphodiesterase 4. Br J Pharmacol 2002;135:609-618.[PMID: 11834608]
15. Salari P, Abdollahi M. Phosphodiesterase inhibitors in inflammatory bowel disease. Expert Opin Investig Drugs 2012;21:261-264.[PMID: 22303952]
16. Manning CD, Burman M, Christensen SB et al. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol 1999;128:1393-1398.[PMID:10602317]
17. Barber R, Baillie GS, Bergmann R et al. Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. Am J Physiol Lung Cell Mol Physiol 2004;287:L332-L343.[PMID:15047569]
18. Bjorgo E, Tasken K. Role of cAMP phosphodiesterase 4 in regulation of T-cell function. Crit Rev Immunol 2006;26:443-451.[PMID: 17341187]
19. Wittmann M, Helliwell PS. Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases. Dermatol Ther (Heidelb) 2013;3:1-15.[PMID: 23888251]
20. Claveau D, Chen SL, O'Keefe S et al. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan- 2-yl)-phenyl]-ethyl]3-methylpyridine-1- oxide], a potent and selective phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther 2004;310:752-760.[PMID: 15082748]
21. Michalski J, Kanaji N, Liu X et al. Attenuation of inhibitory prostaglandin E2 signaling in human lung fibroblasts is mediated by phosphodiesterase 4. Am J Respir Cell Mol Biol 2012;47:729-737.[PMID:23043089]
22. Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbroker D, Bethke TD. Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005;366:563-571.[PMID: 16099292]
23. Rennard SI, Schachter N, Strek M, Rickard K, Amit O. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest 2006;129:56-66.[PMID: 16424413]
24. Rutten-van Molken MP, van Nooten FE, Lindemann M, Caeser M, Calverley PM. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease. Pharmacoeconomics 2007;25:695-711.[PMID:17640111]
25. Schafer PH, Parton A, Gandhi AK et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010;159:842-855.[PMID: 20050849]
26. Gottlieb AB, Strober B, Krueger JG et al. An open- label, single-arm, pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opinion. 2008 May;24(5):1529-38.[PMID: 18419879]
27. Gottlieb AB, Matheson RT, Menter A et al. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. J Drugs Dermatol 2013;12:888-897.[PMID: 23986162]
28. Papp KA, Kaufmann R, Thaci D, Hu C, Sutherland D, Rohane P. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J Eur Acad Dermatol Venereol 2013;27:e376-e383.[PMID: 23030767]
29. Papp K, Cather JC, Rosoph L et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet 2012;380:738-746.[PMID: 22748702]
30. Strand V, Fiorentino D, Hu C, Day RM, Stevens RM, Papp KA. Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study. Health Qual Life Outcomes 2013;11:82.[PMID: 23663752]
31. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64 Suppl 2:ii14-ii17.[PMID: 15708927]
32. Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum 2009;61:233-239.[PMID: 19177544]
33. Schett G, Wollenhaupt J, Papp K et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2012;64:3156-3167.[PMID: 22806399]
34. Volf EM, Au SC, Dumont N, Scheinman P, Gottlieb AB. A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis. J Drugs Dermatol 2012;11:341-346.[PMID: 22395585]
35. Akama T, Baker SJ, Zhang YK et al. Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorg Med Chem Lett 2009;19:2129-2132.[PMID: 19303290]
36. Beutner KR. AN2728 Clinical Data in Psoriasis. 2012. Ref Type: Online Source
37. Beutner KR. AN2728 Clinical Data in Atopic Dermatitis. 2012. Ref Type: Online Source
38. Gutierrez-Ureña S, Molina JF, García CO, Cuéllar ML, Espinoza LR. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum. 1996 Feb;39(2):272-6.[PMID:8849378]
39. Fry L. Psoriasis: Immunopathology and ong-term treatment with cyclosporine. J Autoimmun. 1992 Apr;5 Suppl A:277-83.[PMID: 1503622]
40. Barbero P, Lotersztein V, Bronberg R, Perez M, Alba L. Acitretin embryopathy: a case report. Birth Defects Res A Clin Mol Teratol. 2004 Oct;70(10):831-3.[PMID: 15470719]
41. Sandoval LF, Davis SA, Feldman SR. Dermatologists' knowledge of and preference regarding topical steroids. J Drugs Dermatol 2013;12:786-789.[PMID: 23884491]